GlassScriptPhysician profile
Hebe A Diaz
NPI 1427062884
$597.13
in general payments reported to CMS, 2019-2025
15 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $23.14 · 2021: $108 · 2022: $36.24 · 2023: $140 · 2024: $51.93 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $286 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $285.86 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $163.57 | 2019-2023 | Liletta, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $65.60 | 2022-2025 | |
| Lilly USA, LLC | $58.09 | 2024-2025 | Zepbound |
| Pfizer INC. | $47.92 | 2023-2025 | |
| Organogenesis INC. | $36.64 | 2024-2025 | Affinity |
| Hologic Sales and Service, LLC | $34.93 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $32.85 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $30.37 | 2023 | Exparel |
| Currax Pharmaceuticals LLC | $24.26 | 2019 | |
| Duchesnay USA Incorporated | $23.32 | 2019 | |
| Baxter Healthcare | $23.14 | 2020 | |
| Merck Sharp & Dohme LLC | $19.48 | 2021 | |
| Horizon Therapeutics Plc | $14.73 | 2021 | |
| Astellas Pharma US INC | $13.36 | 2023 | Veozah |
| Intuitive Surgical, INC. | $8.87 | 2023 | Da Vinci Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hebe Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.